(Bloomberg) — The first pill for low libido in women will go on sale in the U.S. after regulators decided that despite its modest benefit and serious side effects, the drug was worthwhile to address an affliction with no other approved treatments.

The Food and Drug Administration said Tuesday that doctors will have to take a training course to be certified to prescribe Sprout Pharmaceuticals Inc.'s Addyi, which will be available as soon as Oct. 17.

And patients must sign a form acknowledging risks that include fainting and extreme sleepiness.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.